Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 94. Отображено 94.
07-06-2012 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES

Номер: US20120141485A1
Автор: Akatsuka Corinne C., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of at least one anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody is selected from Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 , or an antibody or antibody fragment that competes with any of the foregoing antibodies , and/or an antibody or antibody fragment that binds to the same or overlapping epitope as any of the foregoing antibodies.2. The method of of claim 1 , wherein said antibody or antibody fragment inhibits the association of NGF with TrkA claim 1 , and the association of NGF with p75.3. The method of of claim 2 , wherein the administered antibody or antibody fragment is an anti-NGF antibody or antibody fragment that inhibits the association of NGF with TrkA claim 2 , and the association of NGF with p75 claim 2 , and further binds to NGF/TrkA complexes and/or NGF/p75 complexes.4. The method of claim 1 , wherein said antibody fragment is a bivalent or monovalent antibody fragment.5. The method of claim 4 , wherein said monovalent agent is selected from an Fab claim 4 , Fab′ claim 4 , Fv claim 4 , scFv fragments claim 4 , SMIPs (small molecule immunopharmaceuticals) claim 4 , camelbodies claim 4 , nanobodies claim 4 , IgNAR claim 4 , a ...

Подробнее
Номер записи: 1
28-06-2012 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75

Номер: US20120164067A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of an NGF antagonist which inhibits the association of NGF with TrkA , without appreciably inhibiting the association of NGF with p75.2. The method of claim 1 , wherein the NGF antagonist is a polypeptide claim 1 , a fragment of NGF claim 1 , TrkA claim 1 , an antisense or siRNA claim 1 , or an anti-NGF or anti-TrkA antibody or antibody fragment.3. The method of claim 1 , wherein the NGF antagonist is an anti-human NGF antibody or fragment thereof which inhibits the association of NGF with TrkA claim 1 , without appreciably inhibiting the association of NGF with p75.4. The method of claim 3 , wherein the antibody fragment is a monovalent antibody fragment selected from a Fab claim 3 , Fab′ claim 3 , Fv claim 3 , scFv fragments claim 3 , SMIPs (small molecule immunopharmaceuticals) claim 3 , camelbody claim 3 , nanobody claim 3 , IgNAR claim 3 , a monovalent antibody molecule analogous to MetMab claim 3 , or one or more combinations thereof.5. The method of claim 1 , wherein said pain is associated with pre- or post-operative surgery claim 1 , or pain associated with trauma or injury to the musculoskeletal system claim 1 , or the prevention or treatment of chronic visceral pain.6. The method of claim 5 , wherein said ...

Подробнее
Номер записи: 2
29-08-2013 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20130224201A1
Автор: Carvalho-Jensen Ann Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Olson Katie, Smith Jeffrey T.L.
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. 1203-. (canceled)204. A method of inhibiting or treating inflammation comprising the administration of an antibody or antibody fragment to a subject in need thereof , wherein the antibody or antibody fragment comprises the VL CDRS in SEQ ID NO:4 , 5 and 6 , and the VH CDRs in SEQ ID NO:7 , 8 or 120 , and 9 respectively.205. The method of wherein the antibody comprises: (a) light and heavy chain polypeptides at least 90% identical to light and heavy chain polypeptides selected from the group consisting of: SEQ ID NO: 699 and SEQ ID NO: 657; SEQ ID NO: 702 and SEQ ID NO: 704; SEQ ID NO: 706 and SEQ ID NO: 708; SEQ ID NO: 20 and SEQ ID NO: 19; and SEQ ID NO: 2 and SEQ ID NO: 3.206. The method of wherein the antibody comprises: (a) light and heavy chain polypeptides at least 95% identical to light and heavy chain polypeptides selected from the group consisting of: SEQ ID NO: 699 and SEQ ID NO: 657; SEQ ID NO: 702 and SEQ ID NO: 704; SEQ ID NO: 706 and SEQ ID NO: 708; SEQ ID NO: 20 and SEQ ID NO: 19; and SEQ ID NO: 2 and SEQ ID NO: 3.207. The method of wherein the antibody comprises: (a) light and heavy chain polypeptides at least 98% identical to light and heavy chain polypeptides selected from the group consisting of: SEQ ID NO: 699 and SEQ ID NO: 657; SEQ ID NO: 702 and SEQ ID ...

Подробнее
Номер записи: 3
19-12-2013 дата публикации

ANTI-NGF COMPOSITIONS AND USE THEREOF

Номер: US20130336975A1
Автор: Akatsuka Corinne C., Billgren Jens, Chang Betty Yu-Ching, Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., McNeill Patricia Dianne, Mitchell Danielle M., Ojala Ethan W., Stewart Erica A.
Принадлежит:

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF. 1119-. (canceled)120. An anti-human NGF antibody or antibody fragment thereof which specifically binds to the same or overlapping epitope(s) and/or competes for binding to the same or overlapping epitope(s) on an intact NGF polypeptide or fragment thereof as an anti-human NGF antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21 or is an antibody or antibody fragment comprising the same CDRs as any of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21.121. The antibody of claim 120 , wherein:{'sub': '2', '(i) said antibody fragment is selected from an Fab fragment, an Fab′ fragment, scFv, or an F(ab′)fragment;'}{'sub': H', 'L, '(ii) said antibody or fragment comprises a Vpolypeptide at least 90% identical to one selected from those in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 153, 163, 173, 183, 193, or 402 and/or Vpolypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111 ...

Подробнее
Номер записи: 4
26-12-2013 дата публикации

METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS

Номер: US20130344068A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. 1. A method of treating pain in an individual , comprising administering a therapeutically effective amount of an anti-human NGF monovalent agent having binding specificity for NGF that does not substantially increase the inflammatory response of a patient following administration of said monovalent agent.2. The method of claim 1 , wherein said monovalent agent is an Fab claim 1 , Fab′ claim 1 , Fv claim 1 , scFv fragment claim 1 , SMIP (small molecule immunopharmaceutical) claim 1 , camelbody claim 1 , nanobody claim 1 , IgNAR claim 1 , a monovalent antibody molecule analagous to MetMab claim 1 , or one or more combinations thereof.3. The method of claim 1 , wherein the monovalent agent is a Fab antibody fragment comprising a variable light chain comprising the CDR 1 sequence of SEQ ID NO:55 claim 1 , the CDR 2 sequence of SEQ ID NO:56 claim 1 , and the CDR 3 sequence of SEQ ID NO:57 claim 1 , and/or a variable heavy chain comprising the CDR 1 sequence of SEQ ID NO:58 claim 1 , the CDR 2 sequence of SEQ ID NO:59 claim 1 , and the CDR 3 sequence of SEQ ID NO:60.4. The method of claim 1 , wherein the monovalent agent is a Fab antibody fragment or Fab′ claim 1 , Fv claim 1 , scFv fragment claim 1 , SMIP (small molecule immunopharmaceutical) claim 1 , camelbody claim 1 , nanobody claim 1 , IgNAR claim 1 , or a monovalent antibody molecule analagous to MetMab claim 1 , derived from and/or containing one claim 1 , two claim 1 , three claim 1 , four claim 1 , five or all six of the CDRS contained in any one of antibodies Ab1 claim 1 , Ab2 claim 1 , Ab3 claim 1 , Ab4 claim 1 , Ab5 claim 1 , Ab6 claim 1 ...

Подробнее
Номер записи: 5
02-01-2014 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75

Номер: US20140004115A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of an NGF antagonist which inhibits the association of NGF with TrkA , without appreciably inhibiting the association of NGF with p75.2. The method of claim 1 , wherein the NGF antagonist is a polypeptide claim 1 , a fragment of NGF claim 1 , TrkA claim 1 , an antisense or siRNA claim 1 , or an anti-NGF or anti-TrkA antibody or antibody fragment.3. The method of claim 1 , wherein the NGF antagonist is an anti-human NGF antibody or fragment thereof which inhibits the association of NGF with TrkA claim 1 , without appreciably inhibiting the association of NGF with p75.4. The method of claim 3 , wherein the antibody fragment is a monovalent antibody fragment selected from a Fab claim 3 , Fab′ claim 3 , Fv claim 3 , scFv fragments claim 3 , SMIPs (small molecule immunopharmaceuticals) claim 3 , camelbody claim 3 , nanobody claim 3 , IgNAR claim 3 , a monovalent antibody molecule analogous to MetMab claim 3 , or one or more combinations thereof.5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. The method of claim 1 , wherein said method further includes administration of at least one ...

Подробнее
Номер записи: 6
02-01-2014 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES

Номер: US20140004116A1
Автор: Akatsuka Corinne C., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of at least one anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody is selected from Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 , or an antibody or antibody fragment that competes with any of the foregoing antibodies , and/or an antibody or antibody fragment that binds to the same or overlapping epitope as any of the foregoing antibodies.2. The method of claim 1 , wherein said antibody or antibody fragment inhibits the association of NGF with TrkA claim 1 , and the association of NGF with p75.3. The method of claim 2 , wherein the administered antibody or antibody fragment is an anti-NGF antibody or antibody fragment that inhibits the association of NGF with TrkA claim 2 , and the association of NGF with p75 claim 2 , and further binds to NGF/TrkA complexes and/or NGF/p75 complexes.4. The method of claim 1 , wherein said antibody fragment is a bivalent or monovalent antibody fragment or said anti-human NGF antibody is a human claim 1 , humanized claim 1 , single chain claim 1 , or chimeric antibody.5. The method of claim 4 , wherein said monovalent agent is selected from an Fab claim 4 , Fab′ claim 4 , Fv claim 4 , scFv fragments claim 4 , SMIPs ...

Подробнее
Номер записи: 7
18-01-2018 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES

Номер: US20180016331A1
Автор: Akatsuka Corinne C., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Latham John, Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of at least one anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody or antibody fragment selected from Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 , or an anti-human NGF antibody or antibody fragment comprising the same CDRs as any of said anti-human NGF antibodies or antibody fragments.2118-. (canceled)119. An anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody or antibody fragment selected from Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 or an anti-NGF antibody or antibody fragment comprising the same CDRs as any of the foregoing.120. A composition comprising (i) an anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody or antibody fragment is selected from Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 or an anti-NGF antibody or antibody fragment comprising the same CDRs as any of the foregoing and (ii) a pharmaceutically acceptable carrier.121. A vector or nucleic acid which comprises a ...

Подробнее
Номер записи: 8
25-01-2018 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20180022801A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1137-. (canceled)138. An isolated host cell which expresses an anti-human IL-6 antibody or antigen-binding fragment which comprises a variable light (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:4 , 5 and 6 , and a variable heavy (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:7 , 8 or 120 and 9.139. The host cell of claim 138 , wherein the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:4 claim 138 , 5 and 6 claim 138 , and the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:7 claim 138 , 120 and 9.140. The host cell of claim 138 , wherein ...

Подробнее
Номер записи: 9
04-02-2016 дата публикации

PROTOCOL FOR IDENTIFYING AND ISOLATING ANTIGEN-SPECIFIC B CELLS AND PRODUCING ANTIBODIES TO DESIRED ANTIGENS

Номер: US20160033504A1
Автор: Allison Daniel S., Anderson Katie, Billgren Jens, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W.
Принадлежит:

Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies. 1. A method for identifying a B cell that expresses an antigen-specific antibody , comprising:(i) obtaining B cells from a host that has been immunized or exposed naturally to an antigen of interest;(ii) enriching a fraction of said B cells to obtain an enriched population of antigen-specific B cells, which contains a greater percentage of B cells that produce an antibody that binds to the antigen of interest relative to the B cell fraction prior to enrichment;(iii) separately culturing one or more fractions from said enriched antigen-specific B cell population under culture conditions that favor the formation of a clonal B cell population that produces a single antibody that binds to the antigen of interest;(iv) detecting the clonal B cell population that produces a single antibody that binds to the antigen of interest, thereby identifying one or more antigen-specific B cells;(v) optionally screening the clonal antigen-specific B cell population identified in step (iv) to identify B ...

Подробнее
Номер записи: 10
30-01-2020 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES

Номер: US20200031916A1
Автор: Akatsuka Corinne C., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Latham John, Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of at least one anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody is selected from Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 , or an antibody or antibody fragment that comprises the same CDRs as anti-NGF antibody is selected from Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21.2. The method of claim 1 , wherein:(i) said antibody or antibody fragment inhibits the association of NGF with TrkA, and the association of NGF with p75;(ii) the administered antibody or antibody fragment is an anti-NGF antibody or antibody fragment that inhibits the association of NGF with TrkA, and the association of NGF with p75, and further binds to NGF/TrkA complexes and/or NGF/p75 complexes;(iii) said antibody fragment is a bivalent or monovalent antibody fragment;(iv) said antibody fragment is a bivalent or monovalent antibody fragment selected from an Fab, Fab′, Fv, scFv fragments, SMIPs (small molecule immunopharmaceuticals), camelbodies, nanobodies, IgNAR, MetMab, or a combination thereof;(v) the antibody, fragment or monovalent agent is modified to affect circulation time;(vi) the antibody, ...

Подробнее
Номер записи: 11
06-02-2020 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20200040074A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1. An anti-human IL-6 antibody or antibody fragment which specifically binds to the same linear or conformational epitope(s) and/or competes for binding to the same linear or conformational epitope(s) on an intact human IL-6 polypeptide or fragment thereof as an anti-human IL-6 antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , Ab21 , Ab22 , Ab23 , Ab24 , Ab25 , Ab26 , Ab27 , Ab28 , Ab29 , Ab30 , Ab31 , Ab32 , Ab33 , Ab34 , Ab35 , and Ab36 or an anti-IL-6 antibody containing the variable light region contained in any one of the SEQ ID NO:647-651 and a variable heavy chain region contained in any one of SEQ ID NO:s 652-658.2137-. (canceled) This application is a continuation-in-part of U.S. Ser. No. 12/323,066 filed Nov ...

Подробнее
Номер записи: 12
23-02-2017 дата публикации

METHODS OF TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75

Номер: US20170051048A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

This invention pertains to NGF antagonists including antibodies and fragments thereof (including Fab fragments) having binding specificity to human Nerve Growth Factor (hereinafter “NGF”), and methods of using one or more of said antibodies and fragments thereof to treat pain in an individual. More specifically the invention relates to methods of treating pain or eliciting an analgesic effect in an individual, comprising administering an effective amount of an NGF antagonist, e.g., an anti-human NGF antibody or fragment thereof or another moiety, such as a nucleic acid or polypeptide such as a fragment of NGF or TrkA which inhibits the association of NGF with TrkA, without appreciably inhibiting the association of NGF with p75. These methods may optionally further include administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. Another specific embodiment of this invention relates to the use of the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them, in methods of treating pain in an individual. The invention also contemplates the use of conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF, especially pain associated conditions. 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of an NGF antagonist which inhibits the association of NGF with TrkA , without ...

Подробнее
Номер записи: 13
27-02-2020 дата публикации

ANTI-NGF COMPOSITIONS AND USE THEREOF

Номер: US20200062837A1
Автор: Akatsuka Corinne C., Billgren Jens J., Chang Betty Yu-Ching, Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., McNeill Patricia Dianne, Mitchell Danielle M., Ojala Ethan W., Stewart Erica A.
Принадлежит:

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF. 1. An anti-human NGF antibody or antibody fragment which comprises the same CDR polypeptides as an anti-human NGF antibody selected from Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21.25-. (canceled)6. The anti-human NGF antibody or fragment according to claim 1 , wherein said fragment is a Fab fragment comprising a Vpolypeptide at least 90% identical to one selected from those in SEQ ID NO: 3 claim 1 , 13 claim 1 , 23 claim 1 , 33 claim 1 , 43 claim 1 , 53 claim 1 , 63 claim 1 , 73 claim 1 , 83 claim 1 , 93 claim 1 , 103 claim 1 , 113 claim 1 , 123 claim 1 , 133 claim 1 , 143 claim 1 , 153 claim 1 , 163 claim 1 , 173 claim 1 , 183 claim 1 , 193 claim 1 , or 402 and/or Vpolypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1 claim 1 , 11 claim 1 , 21 claim 1 , 31 claim 1 , 41 claim 1 , 51 claim 1 , 61 claim 1 , 71 claim 1 , 81 claim 1 , 91 claim 1 , 101 claim 1 , 111 claim 1 , 121 claim 1 , 131 claim 1 , 141 claim 1 , 151 claim 1 , 161 claim 1 , 171 claim 1 , 181 claim 1 , 191 claim 1 , or 401.721-. (canceled)22. The anti-human NGF antibody or fragment of claim 1 , which is ...

Подробнее
Номер записи: 14
27-02-2020 дата публикации

METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS

Номер: US20200062838A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. 1. A method of treating pain in an individual , comprising administering a therapeutically effective amount of an anti-human NGF monovalent agent having binding specificity for NGF that does not substantially increase the inflammatory response of a patient following administration of said monovalent agent.2. The method of claim 1 , wherein said monovalent agent is an Fab claim 1 , Fab′ claim 1 , Fv claim 1 , scFv fragment claim 1 , SMIP (small molecule immunopharmaceutical) claim 1 , camelbody claim 1 , nanobody claim 1 , IgNAR claim 1 , a monovalent antibody molecule analagous to MetMab claim 1 , or one or more combinations thereof.3. The method of claim 1 , wherein the monovalent agent is a Fab antibody fragment comprising a variable light chain comprising the CDR 1 sequence of SEQ ID NO:55 claim 1 , the CDR 2 sequence of SEQ ID NO:56 claim 1 , and the CDR 3 sequence of SEQ ID NO:57 claim 1 , and/or a variable heavy chain comprising the CDR 1 sequence of SEQ ID NO:58 claim 1 , the CDR 2 sequence of SEQ ID NO:59 claim 1 , and the CDR 3 sequence of SEQ ID NO:60.4. The method of claim 1 , wherein the monovalent agent is a Fab antibody fragment or Fab′ claim 1 , Fv claim 1 , scFv fragment claim 1 , SMIP (small molecule immunopharmaceutical) claim 1 , camelbody claim 1 , nanobody claim 1 , IgNAR claim 1 , or a monovalent antibody comprising the same the CDRS contained in any one of antibodies Ab1 claim 1 , Ab2 claim 1 , Ab3 claim 1 , Ab4 claim 1 , Ab5 claim 1 , Ab6 claim 1 , Ab7 claim 1 , Ab8 claim 1 , Ab9 claim 1 , Ab10 claim 1 , Ab11 claim 1 , Ab12 claim 1 , Ab13 claim 1 , Ab14 claim 1 , Ab15 ...

Подробнее
Номер записи: 15
12-03-2020 дата публикации

Anti-pacap antibodies

Номер: US20200079847A1
Автор: Benjamin H. Dutzar, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee Hendricks, Leon F. Garcia-Martinez, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals Inc

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

Подробнее
Номер записи: 16
19-03-2020 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20200087391A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1. An anti-human IL-6 antibody or antibody fragment which specifically binds to the same linear or conformational epitope(s) and/or competes for binding to the same linear or conformational epitope(s) on an intact human IL-6 polypeptide or fragment thereof as an anti-human IL-6 antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , Ab21 , Ab22 , Ab23 , Ab24 , Ab25 , Ab26 , Ab27 , Ab28 , Ab29 , Ab30 , Ab31 , Ab32 , Ab33 , Ab34 , Ab35 , and Ab36 or an anti-IL-6 antibody containing the variable light region contained in any one of SEQ ID NO:647-651 and a variable heavy chain region contained in any one of SEQ ID NO:s 652-658.2137-. (canceled) This application is a continuation-in-part of U.S. Ser. No. 12/323,066 filed Nov. 25 ...

Подробнее
Номер записи: 17
12-04-2018 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20180100013A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon, Kovacevich Brian R., Latham John, Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1133-. (canceled)134. A method of treating autoimmunity in a subject in need thereof comprising administering to an individual with an autoimmune disorder an effective amount of an anti-human IL-6 antibody or antigen-binding fragment comprising a variable light polypeptide comprising the complementarity regions (CDR's) of SEQ ID NO:4 , 5 and 6 and a variable heavy polypeptide comprising the complementarity regions (CDR's) of SEQ ID NO:7 , 8 or 120 and 9.135. The method of claim 134 , wherein said administered anti-human IL-6 antibody or fragment is a human claim 134 , humanized or chimeric anti-human IL-6 antibody or fragment thereof136. The method of claim 134 , wherein said administered anti-human IL-6 antibody or fragment contains a human Fc region.137. The method of claim 134 , wherein said administered anti-human IL-6 antibody or fragment is of the IgG1 claim 134 , ...

Подробнее
Номер записи: 18
14-05-2015 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20150132224A1
Автор: CARVALHO JENSEN Ann Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Olson Katie, Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1. An anti-human IL-6 antibody or antibody fragment which specifically binds to the same linear or conformational epitope(s) and/or competes for binding to the same linear or conformational epitope(s) on an intact human IL-6 polypeptide or fragment thereof as an anti-human IL-6 antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , Ab21 , Ab22 , Ab23 , Ab24 , Ab25 , Ab26 , Ab27 , Ab28 , Ab29 , Ab30 , Ab31 , Ab32 , Ab33 , Ab34 , Ab35 , and Ab36 or an anti-IL-6 antibody containing the variable light region contained in any one of SEQ ID NO:647-651 or 709 and a variable heavy chain region contained in any one of SEQ ID NO:s 652-658.2153-. (canceled)154. A nucleic acid sequence or nucleic acid sequences which result in the ...

Подробнее
Номер записи: 19
14-05-2015 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75

Номер: US20150132304A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of an NGF antagonist which inhibits the association of NGF with TrkA , without appreciably inhibiting the association of NGF with p75.2. (canceled)3. The method of claim 1 , wherein the NGF antagonist is an anti-human NGF antibody or fragment thereof which inhibits the association of NGF with TrkA claim 1 , without appreciably inhibiting the association of NGF with p75.4. The method of claim 3 , wherein the antibody fragment is a monovalent antibody fragment selected from a Fab claim 3 , Fab′ claim 3 , Fv claim 3 , scFv fragments claim 3 , SMIPs (small molecule immunopharmaceuticals) claim 3 , camelbody claim 3 , nanobody claim 3 , IgNAR claim 3 , a monovalent antibody molecule analogous to MetMab claim 3 , or one or more combinations thereof.5. The method of claim 1 , wherein said pain is associated with pre- or post-operative surgery claim 1 , or pain associated with trauma or injury to the musculoskeletal system claim 1 , or the prevention or treatment of chronic visceral pain.6. The method of claim 5 , wherein said chronic visceral pain is due to a physiological disorder selected from dysmenorrhoea claim 5 , dyspepsia claim 5 , gastrooesophageal reflux claim 5 , pancreatitis claim 5 , visceralgia and irritable bowel ...

Подробнее
Номер записи: 20
18-05-2017 дата публикации

ANTIBODY PURIFICATION AND PURITY MONITORING

Номер: US20170137500A1
Автор: Allison Daniel S., Davin Steven D., Do Hoa Binh, Garcia-Martinez Leon F., Latham John A., Lee Geoffrey F., Ojala Ethan W., Young Mark
Принадлежит:

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as , and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant. 1100-. (canceled)101. A process for purifying a desired recombinant polypeptide from one or more samples resulting from a fermentation process that comprises culturing a desired cell or microbe under conditions that result in the expression and secretion of the recombinant polypeptide and one or more impurities into the fermentation medium; wherein the purification process includes detecting the amount and/or type of glycosylated impurities in the sample(s) using a lectin that binds to said glycosylated impurities , and which process optionally further comprises contacting the sample(s) with at least one chromatographic support and separating the desired recombinant polypeptide , which method optionally comprises detecting the amount and/or type of glycosylated impurities in the eluate or fractions thereof using a lectin that binds to said glycosylated impurities , further wherein the lectin optionally includes at least one lectin selected from ConA , LCH , GNA or GNL , RCA , DC-SIGN , L-SIGN , PNA , AIL , VVL , WGA , SNA , MAL , MAH , UEA and AAL , and/or at least one ...

Подробнее
Номер записи: 21
18-05-2017 дата публикации

METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS

Номер: US20170137508A1
Автор: Dutzar Benjamin H., Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. 1. A method of treating pain or eliciting an analgesic effect in an individual , comprising administering an effective amount of at least one anti-human NGF antibody or fragment thereof , wherein the anti-NGF antibody is selected from Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21 or comprises an antigen binding fragment thereof , or comprises an anti-human NGF antibody or antibody fragment comprising the same CDRs as any of Ab1 , Ab2 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab17 , Ab18 , Ab19 , Ab20 , or Ab21.2. The method of claim 1 , wherein said antibody or antibody fragment inhibits the association of NGF with TrkA claim 1 , and the association of NGF with p75.3. The method of claim 2 , wherein the administered antibody or antibody fragment is an anti-NGF antibody or antibody fragment that inhibits the association of NGF with TrkA claim 2 , and the association of NGF with p75 claim 2 , and further binds to NGF/TrkA complexes and/or NGF/p75 complexes.4. The method of claim 1 , wherein said antibody fragment is a bivalent or monovalent antibody fragment or said anti-human NGF antibody is a human claim 1 , humanized claim 1 , single chain claim 1 , or chimeric antibody.5. The method of claim 4 , wherein said monovalent agent is selected from an Fab claim 4 , Fab′ claim 4 , Fv claim 4 , say fragments claim 4 , SMIPs (small molecule immunopharmaceuticals) claim 4 , camelbodies claim 4 , nanobodies claim 4 , IgNAR claim 4 , a monovalent antibody molecule analogous to MetMab claim 4 , or one or more ...

Подробнее
Номер записи: 22
24-05-2018 дата публикации

ANTI-GLYCOPROTEIN ANTIBODIES AND USES THEREOF

Номер: US20180142038A1
Автор: Allison Daniel S., BROWN Pamela, DUTZAR Benjamin, Lee Geoffrey F., Mulligan Jenny A., Ojala Ethan W., SINGH AMARJEET
Принадлежит: ALDER BIOPHARMACEUTICALS, INC. a/b/a ALDERBIO HOLDINGS LLC

A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated proteins, such as proteins produced by fungi. Assays using these anti-glycoprotein antibodies for monitoring the presence of glycoproteins in a sample are provided. Such methods can be used to monitor methods for production and/or purification of desired polypeptides, which may be used to modify process parameters to modify (e.g., decrease or increase) the amount of glycosylated polypeptide produced and/or present in the purified product. Also provided are methods of using the subject antibodies for detecting the level of expression and secretion of a polypeptide, and methods of using the subject antibodies to purify or deplete a glycoprotein from a sample. In exemplary embodiments, the desired polypeptide may be a multi-subunit protein, such as an antibody, which may be produced in a yeast, such as 1. An anti-glycoprotein antibody or antibody fragment which specifically binds to the same or overlapping linear or conformational epitope(s) on a glycoprotein and/or competes for binding to the same or overlapping linear or conformational epitope(s) on a glycoprotein as an anti-glycoprotein antibody selected from Ab1 , Ab2 , Ab3 , Ab4 , or Ab5.2. The anti-glycoprotein antibody or antibody fragment of claim 1 , wherein:(a) said antibody or antibody fragment specifically binds to the same or overlapping linear or conformational epitope(s) and/or competes for binding to the same or overlapping linear or conformational epitope(s) on a glycoprotein as the anti-glycoprotein antibody Ab1;(b) said antibody fragment is selected from an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a monovalent antibody, or a metMab;(c) said antibody fragment is a Fab fragment;(d) said antibody or antibody fragment comprises the same complementarity determining regions (CDRs) as an anti-glycoprotein antibody selected from Ab1, Ab2, Ab3, ...

Подробнее
Номер записи: 23
15-09-2022 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20220289836A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications. 1311-. (canceled)312. An anti-human Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof that antagonizes , inhibits , neutralizes or blocks at least one biological effect associated with human PACAP , wherein said anti-human PACAP antibody or antigen binding fragment thereof comprises the same variable light (VL) and variable heavy (VH) polypeptides as any one of Ab1 , Ab2 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab1.H , Ab5 , Ab7 , Ab11 , Ab12 , Ab4 , Ab3 , Ab6 , Ab8 , and Ab9.313. A nucleic acid or nucleic acids which encode for an anti-human Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof that antagonizes , inhibits , neutralizes or blocks at least one biological effect associated with human PACAP , wherein said human , humanized or chimerized anti-human PACAP antibody or antigen binding fragment thereof comprises the same variable light (VL) and variable heavy (VH) polypeptides as any one ...

Подробнее
Номер записи: 24
17-06-2021 дата публикации

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20210179688A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 1. A humanized anti-PACAP antibody or antigen binding fragment which comprises the same-complementarity determining regions (“CDRs”) as as Ab10.H , Ab10.H2 , Ab10.H3 , Ab10.H4 , Ab10.H5 , Ab10.H6 , Ab21 , Ab21.H , Ab21.H2 , Ab21.H3 , or Ab21.H4.231-. (canceled)32. An isolated nucleic acid sequence or nucleic acid sequences encoding an anti-PACAP antibody or antigen binding fragment according to claim 1 , or a vector or vectors contains said isolated nucleic acid sequence or sequences.33. A host cell comprising the isolated nucleic acid sequence or sequences or the vector or vectors of .34. A method of expressing an anti-PACAP antibody or antigen binding fragment comprising culturing the host cell of under conditions that provide for expression of said antibody or antigen binding fragment.3558-. (canceled)59. A method for blocking claim 33 , inhibiting or neutralizing ...

Подробнее
Номер записи: 25
28-05-2020 дата публикации

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20200165316A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 158-. (canceled)59. A humanized anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1282 and a light chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1302 ,wherein said heavy chain variable region comprises the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 1284, the heavy chain CDR2 polypeptide of SEQ ID NO: 1286, and the heavy chain CDR3 polypeptide of SEQ ID NO: 1288, andsaid light chain variable region comprises the light chain CDR1 polypeptide of SEQ ID NO: 1304, the light chain CDR2 polypeptide of SEQ ID NO: 1306, and the light chain CDR3 polypeptide of SEQ ID NO: 1308.60. The humanized anti-PACAP antibody or antigen binding fragment thereof of ...

Подробнее
Номер записи: 26
04-06-2020 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20200172612A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications. 1191-. (canceled)192. A humanized anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide comprising the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 404 , the heavy chain CDR2 polypeptide of SEQ ID NO: 406 , and the heavy chain CDR3 polypeptide of SEQ ID NO: 408 , and a light chain variable region comprising the light chain CDR1 polypeptide of SEQ ID NO: 424 , the light chain CDR2 polypeptide of SEQ ID NO: 426 , and the light chain CDR3 polypeptide of SEQ ID NO: 428.193. The humanized anti-PACAP antibody or antigen binding fragment thereof of claim 192 , which comprises a heavy chain variable region polypeptide having at least 90% identity to the polypeptide of SEQ ID NO: 402.194. The humanized anti-PACAP antibody or antigen binding fragment thereof of claim 192 , which comprises a light chain variable region polypeptide having at least 90% identity to the polypeptide of ...

Подробнее
Номер записи: 27
16-07-2015 дата публикации

Antibodies to il-6 and use thereof

Номер: US20150197567A1
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T.L. Smith, John Latham, Katie Anderson, Leon Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V II , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 28
05-07-2018 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20180186874A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1153-. (canceled)154. A method of producing an anti-IL-6 antibody comprising a light chain polypeptide or variable light chain polypeptide and a heavy chain polypeptide or variable heavy chain polypeptide , said method comprising culturing a recombinant cell which expresses a first nucleic acid sequence encoding said heavy chain polypeptide or variable heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2 , 20 , 702 , 706 and 709; and which recombinant cell further expresses a second nucleic acid sequence encoding a light chain polypeptide or variable light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:3 , 18 , 19 , 657 , 658 , 704 and 708.155. The method of wherein the first or second nucleic acid sequence is comprised of yeast or ...

Подробнее
Номер записи: 29
11-06-2020 дата публикации

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20200181229A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 158-. (canceled)59. A humanized anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1322 and a light chain variable region polypeptide having at least 90% identity to SEQ ID NO: 1342 ,wherein said heavy chain variable region comprises the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 1324, the heavy chain CDR2 polypeptide of SEQ ID NO: 1326, and the heavy chain CDR3 polypeptide of SEQ ID NO: 1328, andsaid light chain variable region comprises the light chain CDR1 polypeptide of SEQ ID NO: 1344, the light chain CDR2 polypeptide of SEQ ID NO: 1346, and the light chain CDR3 polypeptide of SEQ ID NO: 1348.60. The humanized anti-PACAP antibody or antigen binding fragment thereof of ...

Подробнее
Номер записи: 30
11-06-2020 дата публикации

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20200181230A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 158-. (canceled)59. A humanized anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising a heavy chain variable region polypeptide having at least 90% identity to SEQ ID NO: 962 and a light chain variable region polypeptide having at least 90% identity to SEQ ID NO: 982 ,wherein said heavy chain variable region comprises the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 964, the heavy chain CDR2 polypeptide of SEQ ID NO: 966, and the heavy chain CDR3 polypeptide of SEQ ID NO: 968, andsaid light chain variable region comprises the light chain CDR1 polypeptide of SEQ ID NO: 984, the light chain CDR2 polypeptide of SEQ ID NO: 986, and the light chain CDR3 polypeptide of SEQ ID NO: 988.60. The humanized anti-PACAP antibody or antigen binding fragment thereof of claim 59 , ...

Подробнее
Номер записи: 31
22-07-2021 дата публикации

Anti-pacap antibodies

Номер: US20210221884A9
Автор: Benjamin H. Dutzar, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee Hendricks, Leon F. Garcia-Martinez, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

Подробнее
Номер записи: 32
25-09-2014 дата публикации

ANTIBODY PURIFICATION AND PURITY MONITORING

Номер: US20140288272A1
Автор: Allison Daniel S., Davin Steven D., Do Hoa Binh, Garcia-Martinez Leon F., Latham John A., Lee Geoffrey F., Ojala Ethan W., Young Mark
Принадлежит: ALDERBIO HOLDINGS LLC

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as , and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant. 1100-. (canceled)101. A process for purifying a desired recombinant polypeptide from one or more samples resulting from a fermentation process that comprises culturing a desired cell or microbe under conditions that result in the expression and secretion of the recombinant polypeptide and one or more impurities into the fermentation medium; wherein the purification process includes detecting the amount and/or type of glycosylated impurities in the sample(s) using a lectin that binds to said glycosylated impurities , and which process optionally further comprises contacting the sample(s) with at least one chromatographic support and separating the desired recombinant polypeptide , which method optionally comprises detecting the amount and/or type of glycosylated impurities in the eluate or fractions thereof using a lectin that binds to said glycosylated impurities , further wherein the lectin optionally includes at least one lectin selected from ConA , LCH , GNA or GNL , RCA , DC-SIGN , L-SIGN , PNA , AIL , VVL , WGA , SNA , MAL , MAH , UEA and AAL , and/or at least one ...

Подробнее
Номер записи: 33
19-07-2018 дата публикации

In vivo Imaging using Anti-IL-6 Antibodies

Номер: US20180201668A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab 1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. 1203-. (canceled)204. A method of in vivo imaging which detects the presence of cells which express IL-6 comprising administering an effective amount of at least one anti-IL-6 antibody or antibody fragment , wherein said wherein the antibody or antibody fragment comprises: a variable light chain polypeptide comprising: a polypeptide having at least 90% identity to SEQ ID NO: 709 , and a variable heavy chain polypeptide comprising: a polypeptide having at least 90% identity to SEQ ID NO: 657 , further wherein said anti-IL-6 antibody or antibody fragment comprises the variable light chain complementarity determining region (CDR) polypeptides of SEQ ID NO:4 , 5 and 6 and comprises the variable heavy chain complementarity determining region (CDR) polypeptides of SEQ ID NO:7 , 8 or 120 , and 9 , and wherein said administration further includes the administration of a radionuclide or fluorophore that facilitates detection of the antibody at IL-6 expressing disease sites.205. The method of claim 204 , wherein said in vivo imaging is used to detect IL-6 expressing tumors or metastases in a subject with cancer or metastasis.206. The method of claim 204 , wherein said in vivo imaging is used to detect IL-6 expressing cells at sites of pathology in a subject with a chronic autoimmune ...

Подробнее
Номер записи: 34
19-07-2018 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20180201675A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1153-. (canceled)154. A method of treating an inflammatory condition associated with elevated IL-6 which comprises administering a therapeutically effective amount of an anti-human IL-6 antibody or anti-human IL-6 antibody fragment which comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 709 , and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 657.155. A method of treating an inflammatory condition which comprises administering a therapeutically effective amount of an anti-human IL-6 antibody or anti-human IL-6 antibody fragment which comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 709 and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 656.156. The method of claim 154 , wherein said anti-human IL-6 antibody or anti-human IL-6 ...

Подробнее
Номер записи: 35
12-08-2021 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20210246201A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1137-. (canceled)138. A method of treatment or prevention of adult respiratory distress syndrome (ARDS) , severe acute respiratory syndrome (SARS) , sepsis , or systemic inflammatory response syndrome (SIRS) in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody or anti-human IL-6 antibody fragment , wherein the antibody or antibody fragment comprises: a variable light chain polypeptide comprising the CDRs of SEQ ID NOs:4 , 5 and 6 and , and a variable heavy chain polypeptide comprising the CDRs of SEQ ID NOs:7 , 8 or 120 , and 9.139. The method of claim 138 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 20 and a VH polypeptide of SEQ ID NO: 19.140. The method of claim 138 , wherein the antibody comprises a VL ...

Подробнее
Номер записи: 36
16-07-2020 дата публикации

ANTIBODY PURIFICATION AND PURITY MONITORING

Номер: US20200223913A1
Автор: Allison Daniel S., Davin Steven D., Do Hoa Binh, Garcia-Martinez Leon F., Latham John A., Lee Geoffrey F., Ojala Ethan W., Young Mark
Принадлежит:

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as , and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant. 1. A process for purifying a desired recombinant polypeptide from one or more samples resulting from a fermentation process that comprises culturing a desired cell or microbe under conditions that result in the expression and secretion of the recombinant polypeptide and one or more impurities into the fermentation medium; wherein the purification process includes detecting the amount and/or type of glycosylated impurities in the sample(s) using a lectin that binds to said glycosylated impurities.2. The process of claim 1 , wherein:(i) said process further comprises contacting the sample(s) with at least one chromatographic support and separating the desired recombinant polypeptide, optionally wherein said process further comprises detecting the amount and/or type of glycosylated impurities in the eluate or fractions thereof using a lectin that binds to said glycosylated impurities;(ii) wherein the detection step is effected using at least one lectin selected from ConA LCH, GNA or GNL, RCA, DC-SIGN, L-SIGN, PNA, AIL, VVL, WGA, SNA, MAL, MAH, UEA and AAL, optionally wherein ...

Подробнее
Номер записи: 37
01-08-2019 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20190233498A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon, Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 1. A humanized anti-PACAP antibody or antigen binding fragment which specifically binds to the same or overlapping linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody selected from Ab3.H , Ab4.H , Ab5.H , Ab9 , Ab9.H and Ab12.H.2. (canceled)3. The anti-PACAP antibody or antigen binding fragment of claim 1 , which does not substantially interact with (bind) Vasoactive Intestinal Peptide (“VIP”).4. The anti-PACAP antibody or antigen binding fragment of claim 1 , which comprises or elicits one of the following effects: (a) inhibits or neutralizes at least one biological effect elicited by PACAP; (b) neutralizes or inhibits PACAP activation of at least one of PAC1 receptor (“PAC1-R”) claim 1 , vasoactive intestinal peptide receptor type 1 (“VPAC1-R”) claim 1 , and/or vasoactive intestinal peptide receptor type 2 (“VPAC2-R”); (c) neutralizes or ...

Подробнее
Номер записи: 38
09-09-2021 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20210277106A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications. 1191-. (canceled)192. An anti-Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen binding fragment thereof comprising:(a) a heavy chain variable region (VH) polypeptide comprising the heavy chain complementarity-determining region (CDR) 1 polypeptide of SEQ ID NO: 404, the heavy chain CDR2 polypeptide of SEQ ID NO: 406, and the heavy chain CDR3 polypeptide of SEQ ID NO: 408; and(b) a light chain variable region (VL) comprising the light chain CDR1 polypeptide of SEQ ID NO: 424, the light chain CDR2 polypeptide of SEQ ID NO: 426, and the light chain CDR3 polypeptide of SEQ ID NO: 428.193. A nucleic acid encoding an anti-PACAP antibody or antigen binding fragment according to or a vector comprising said nucleic acid.194. A host cell comprising a nucleic acid encoding an anti-PACAP antibody or antigen binding fragment according to or a vector comprising said nucleic acid.195. A method of making an anti-PACAP antibody or antigen binding fragment according to comprising culturing a host ...

Подробнее
Номер записи: 39
17-09-2015 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20150259413A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon, Kovacevich Brian R., Latham John, Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1137-. (canceled)138. A vector that encodes for an anti-human IL-6 antibody or antigen-binding fragment wherein the anti-human IL-6 antibody or antibody fragment comprises: a variable light (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:4 , 5 and 6 , and a variable heavy (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:7 , 8 or 120 and 9.139. The vector of claim 138 , wherein the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:4 claim 138 , 5 and 6 claim 138 , and the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:7 claim 138 , 120 and 9. ...

Подробнее
Номер записи: 40
01-10-2015 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20150274823A1
Автор: Anderson Katie Olson, CARVALHO JENSEN Ann Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1153-. (canceled)154. An anti-human IL-6 antibody or anti-human IL-6 antibody fragment which comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 647 , 648 , 649 , 650 , 651 , 660 , 666 , 699 , 702 , 706 , or 709 , and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 652 , 653 , 654 , 655 , 656 , 657 , 661 , 664 , 665 , 657 , 658 , 704 , or 708.155. The anti-human IL-6 antibody or anti-human IL-6 antibody fragment which comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 709 , and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 657.156. The anti-human IL-6 antibody or anti-human IL-6 antibody fragment of claim 154 , which comprises a variable light chain comprising the amino acid sequence of SEQ ID NO:709 and a variable heavy chain ...

Подробнее
Номер записи: 41
05-09-2019 дата публикации

USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA

Номер: US20190270807A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Katherine Lee, Karasek Charlie, Kuburas Adisa, Latham John A., Loomis Maria-Cristina, MASON Bianca, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Russo Andrew F., Scalley-Kim Michelle, Smith Jeffrey T.L., SOWERS Levi P., Stewart Erica
Принадлежит:

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof 1. A method of screening for an antibody or antigen binding fragment suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion , or precluding the onset of PACAP-associated photophobia or light aversion , in a subject in need thereof , which comprises:(i) providing at least one first test subject and at least one second test subject;(ii) administering PACAP to the at least one first test subject and the at least one second test subject;(iii) further administering to the at least one first test subject one or more anti-PACAP antibodies, anti-Pituitary Adenylate Cyclase Activating Polypeptide type 1 Receptor (PAC1-R) antibodies, anti-vasoactive intestinal peptide receptor type 1 (VPAC1-R) antibodies, or anti-vasoactive intestinal peptide receptor type 2 (VPAC2-R) antibodies, or an antigen binding fragment of any of the foregoing;(iv) comparing the response of the at least one first test subject and at least one second test subject to light; and(v) based on this comparison, identifying one or more antibodies or antigen binding fragments thereof that yield a decreased light aversion or decreased photophobia in the at least one first test subject as compared with the at least one second test subject, thereby identifying an antibody or antigen binding fragment suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a subject in need thereof, with the proviso that none of said anti-PACAP ...

Подробнее
Номер записи: 42
20-10-2016 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20160304604A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications. 1191-. (canceled)192. A human , humanized or chimerized anti-human Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antibody fragment selected from the following:(i) that antagonizes, inhibits, neutralizes or blocks at least one biological effect associated with human PACAP;(ii) one that that specifically competes for binding to human PACAP with an antibody selected from the group consisting of Ab10 and Ab20 or an antigen-binding fragment of any one of the foregoing;(iii) one that specifically binds to at least one linear or conformational epitope bound by an anti-PACAP antibody selected from the group consisting of Ab10 and Ab20 or an antigen-binding fragment of any one of the foregoing; (a) at least one of residues 19, 22, 23 and 27 of human PACAP;', '(b) at least one of residues 19, 22, 23, 24 and 27 of human PACAP;', '(c) at least two of the residues of any one of (i)-(ii);', '(d) at least three of the residues of any one of (i)-(ii);', '(e) at least four of the residues of any one of ( ...

Подробнее
Номер записи: 43
19-10-2017 дата публикации

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20170298115A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 1. A humanized anti-PACAP antibody or antigen binding fragment which specifically binds to the same or overlapping linear or conformational epitope(s) on human PACAP as Ab10.H , Ab10.H2 , Ab10.H3 , Ab10.H4 , Ab10.H5 , Ab10.H6 , Ab21 , Ab21.H , Ab21.H2 , Ab21.H3 , or Ab21.H4 , or which specifically binds to the same or overlapping linear or conformational epitope(s) on human PACAP as Ab22 or Ab23 , or which specifically binds to the same or overlapping linear or conformational epitope(s) on human PACAP as Ab21.H , Ab21.H2 , Ab21.H3 , or Ab21.H4.2. (canceled)3. The anti-PACAP antibody or antigen binding fragment of claim 1 , which does not substantially interact with (bind) Vasoactive Intestinal Peptide (“VIP”).4. The anti-PACAP antibody or antigen binding fragment of claim 1 , which comprises or elicits one of the following effects: (a) inhibits or neutralizes at least ...

Подробнее
Номер записи: 44
19-10-2017 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20170298127A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon, Hendrix Katherine Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial. 1. A humanized anti-PACAP antibody or antigen binding fragment which specifically binds to the same or overlapping linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody selected from Ab3.H , Ab4.H , Ab5.H , Ab9 , Ab9.H and Ab12.H.2. (canceled)3. The anti-PACAP antibody or antigen binding fragment of claim 1 , which does not substantially interact with (bind) Vasoactive Intestinal Peptide (“VIP”).4. The anti-PACAP antibody or antigen binding fragment of claim 1 , which comprises or elicits one of the following effects: (a) inhibits or neutralizes at least one biological effect elicited by PACAP; (b) neutralizes or inhibits PACAP activation of at least one of PAC1 receptor (“PAC1-R”) claim 1 , vasoactive intestinal peptide receptor type 1 (“VPAC1-R”) claim 1 , and/or vasoactive intestinal peptide receptor type 2 (“VPAC2-R”); (c) neutralizes or ...

Подробнее
Номер записи: 45
19-11-2015 дата публикации

METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES

Номер: US20150329625A1
Автор: Akatsuka Corinne C., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.)

Подробнее
Номер записи: 46
26-11-2015 дата публикации

Antibodies to tnf alpha and use thereof

Номер: US20150337035A1
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Ethan W. Ojala, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-α. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-α antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-α antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-α antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-α.

Подробнее
Номер записи: 47
26-11-2015 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20150337036A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. 1203-. (canceled)204. A method of treating a chronic disease associated with reduced hemoglobulin comprising administration of an anti-interleukin-6 (“IL-6”) antibody or antibody fragment to a subject in need thereof , wherein the antibody or antibody fragment comprises a variable light (V) chain having the complementarity determining regions (CDRs) of SEQ ID NO:4 , 5 and 6 , and a variable heavy (V) chain having the CDRs of SEQ ID NO:7 , 8 or 120 , and 9 , respectively , and wherein the administration of said antibody increases or maintains the hemoglobin levels in said patient.205. The method of claim 204 , which comprises detecting hemoglobin levels before treatment.206. The method of claim 204 , which comprises detecting hemoglobin levels after treatment.207. The method of claim 204 , which comprises detecting hemoglobin levels before and after treatment.208. The method of claim 204 , wherein the antibody or antibody fragment comprises (a) a Vchain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:699 claim 204 , SEQ ID NO:20 or SEQ ID NO:2 claim 204 , and (b) a Vchain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:657 claim 204 , SEQ ID NO:19 claim 204 , or SEQ ID NO:3.209. The ...

Подробнее
Номер записи: 48
16-11-2017 дата публикации

ANTI-NGF COMPOSITIONS AND USE THEREOF

Номер: US20170327568A1
Автор: Akatsuka Corinne C., Billgren Jens J., Chang Betty Yu-Ching, Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., Kovacevich Brian R., Latham John A., McNeill Patricia Dianne, Mitchell Danielle M., Ojala Ethan W., Stewart Erica A.
Принадлежит:

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF. 1144-. (canceled)145. An anti-human NGF antibody or NGF binding antibody fragment thereof which comprises the same CDRs as an anti-human NGF antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21.146. A therapeutic composition comprising an anti-human NGF antibody or NGF binding antibody fragment thereof according to and a pharmaceutically acceptable carrier.147. A diagnostic composition comprising an anti-human NGF antibody or NGF binding antibody fragment thereof according to and a diagnostically acceptable carrier.148. The antibody of claim 145 , wherein said antibody fragment is selected from an Fab fragment claim 145 , an Fab′ fragment claim 145 , scFv claim 145 , or an F(ab′)fragment.149. The antibody of claim 145 , wherein:{'sub': H', 'L, 'said antibody or fragment comprises a Vpolypeptide at least 90% identical to one selected from those in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 153, 163, 173, 183, 193, or 402 and/or Vpolypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51 ...

Подробнее
Номер записи: 49
15-12-2016 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US20160361441A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Lee HENDRICKS, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals Inc, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 50
15-12-2016 дата публикации

ANTI-PACAP ANTIBODIES AND USES THEREOF

Номер: US20160362488A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Lee, Karasek Charlie, Latham John A., Loomis Maria-Cristina, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Scalley-Kim Michelle, Smith Jeffrey T.L., Stewart Erica
Принадлежит:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications. 1. An antibody or antibody fragment selected from the following:(a) a human, humanized or chimerized anti-human Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antibody fragment that antagonizes, inhibits, neutralizes or blocks at least one biological effect associated with human PACAP;(b) a human, humanized or chimerized anti-PACAP antibody or antibody fragment that specifically competes for binding to human PACAP with an antibody selected from the group consisting of Ab1, Ab2, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab1.H, Ab5, Ab7, Ab11, Ab12, Ab4, Ab3, Ab6, Ab8, and Ab9 or an antigen-binding fragment of any one of the foregoing;(c) a human, humanized or chimerized anti-PACAP antibody or antibody fragment that specifically binds to at least one linear or conformational epitope bound by an anti-PACAP antibody selected from the group consisting of Ab1, Ab2, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab1.H, Ab5, Ab7, Ab11, Ab12, Ab4, Ab3, Ab6, Ab8, and Ab9 or an antigen-binding fragment ...

Подробнее
Номер записи: 51
24-12-2015 дата публикации

Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75

Номер: US20150368330A1
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T.L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.

Подробнее
Номер записи: 52
29-12-2016 дата публикации

USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA

Номер: US20160376363A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Lee, Karasek Charlie, Kuburas Adisa, Latham John A., Loomis Maria-Cristina, MASON Bianca, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Russo Andrew F., Scalley-Kim Michelle, Smith Jeffrey T.L., SOWERS Levi P., Stewart Erica
Принадлежит:

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof. 1. A method of screening for an antibody or antigen binding fragment suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion , or precluding the onset of PACAP-associated photophobia or light aversion , in a subject in need thereof , which comprises:(i) providing at least one first test subject and at least one second test subject;(ii) administering PACAP to the at least one first test subject and the at least one second test subject;(iii) further administering to the at least one first test subject one or more anti-PACAP antibodies, anti-Pituitary Adenylate Cyclase Activating Polypeptide type 1 Receptor (PAC1-R) antibodies, anti-vasoactive intestinal peptide receptor type 1 (VPAC1-R) antibodies, or anti-vasoactive intestinal peptide receptor type 2 (VPAC2-R) antibodies, or an antigen binding fragment of any of the foregoing;(iv) comparing the response of the at least one first test subject and at least one second test subject to light; and(v) based on this comparison, identifying one or more antibodies or antigen binding fragments thereof that yield a decreased light aversion or decreased photophobia in the at least one first test subject as compared with the at least one second test subject, thereby identifying an antibody or antigen binding fragment suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a subject in need thereof.2. A method of screening for an antibody or antigen ...

Подробнее
Номер записи: 53
27-12-2018 дата публикации

Antibodies to il-6 and use thereof

Номер: US20180371079A1
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T.L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 54
21-07-2015 дата публикации

Antibodies to IL-6 to inhibit or treat inflammation

Номер: US9085615B2
Автор: Ann Elisabeth CARVALHO JENSEN, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Подробнее
Номер записи: 55
08-08-2017 дата публикации

Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody

Номер: US9725509B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Katie Anderson, Leon Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.

Подробнее
Номер записи: 56
05-12-2017 дата публикации

Antibodies to IL-6 and use thereof

Номер: US9834603B2
Автор: Ann Elisabeth CARVALHO JENSEN, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Olson ANDERSON, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 57
13-10-2020 дата публикации

Methods of treating autoimmunity using specific anti-IL-6 antibodies

Номер: US10800841B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Katie Anderson, Leon Garcia-Martinez
Принадлежит: Vitaeris Inc

Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.

Подробнее
Номер записи: 58
01-09-2020 дата публикации

Antibodies to IL-6 and use thereof

Номер: US10759853B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 59
09-02-2021 дата публикации

Antibodies to IL-6 and use thereof

Номер: US10913794B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: Vitaeris Inc

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 60
19-03-2019 дата публикации

Isolated host cells expressing anti-IL-6 antibodies

Номер: US10233239B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 61
09-07-2019 дата публикации

Antibodies to IL-6 and use thereof

Номер: US10344086B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 62
26-09-2017 дата публикации

Treating anemia in chronic IL-6 associated diseases using anti-IL-6 antibodies

Номер: US9771421B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Katie Anderson, Leon Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

Methods of treating anemia in chronic diseases where IL-6 is elevated using IL-6 antagonist antibodies are provided.

Подробнее
Номер записи: 63
30-01-2018 дата публикации

Antibodies to IL-6 and use thereof

Номер: US9879074B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Подробнее
Номер записи: 64
16-12-2014 дата публикации

Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75

Номер: US8911734B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.

Подробнее
Номер записи: 65
30-06-2015 дата публикации

Methods of preventing or treating pain using anti-NGF antibodies

Номер: US9067988B2
Автор: Benjamin H. Dutzar, Corinne C. Akatsuka, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Leon F. Garcia-Martinez, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.)

Подробнее
Номер записи: 66
14-07-2015 дата публикации

Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75

Номер: US9078878B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.

Подробнее
Номер записи: 67
10-01-2017 дата публикации

Methods of preventing inflammation and treating pain using anti-NGF compositions

Номер: US9539324B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.

Подробнее
Номер записи: 68
06-02-2018 дата публикации

Anti-NGF compositions and use thereof

Номер: US9884909B2
Автор: Benjamin H. Dutzar, Betty Yu-Ching Chang, Brian R. Kovacevich, Corinne C. Akatsuka, Danielle M. Mitchell, Erica A. Stewart, Ethan W. Ojala, Jens Billgren, John A. Latham, Leon F. Garcia-Martinez, Patricia Dianne Mcneill, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Подробнее
Номер записи: 69
22-08-2017 дата публикации

Methods of preventing or treating pain using anti-NGF antibodies

Номер: US9738713B2
Автор: Benjamin H. Dutzar, Corinne C. Akatsuka, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA).

Подробнее
Номер записи: 70
05-03-2019 дата публикации

Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75

Номер: US10221236B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to NGF antagonists including antibodies and fragments thereof (including Fab fragments) having binding specificity to human Nerve Growth Factor (hereinafter “NGF”), and methods of using one or more of said antibodies and fragments thereof to treat pain in an individual. More specifically the invention relates to methods of treating pain or eliciting an analgesic effect in an individual, comprising administering an effective amount of an NGF antagonist, e.g., an anti-human NGF antibody or fragment thereof or another moiety, such as a nucleic acid or polypeptide such as a fragment of NGF or TrkA which inhibits the association of NGF with TrkA, without appreciably inhibiting the association of NGF with p75. These methods may optionally further include administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA. Another specific embodiment of this invention relates to the use of the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them, in methods of treating pain in an individual. The invention also contemplates the use of conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF, especially pain associated conditions.

Подробнее
Номер записи: 71
01-08-2017 дата публикации

Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75

Номер: US9718882B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.

Подробнее
Номер записи: 72
10-10-2017 дата публикации

Anti-NGF compositions and use thereof

Номер: US9783602B2
Автор: Benjamin H. Dutzar, Betty Yu-Ching Chang, Brian R. Kovacevich, Corinne C. Akatsuka, Danielle M. Mitchell, Erica A. Stewart, Ethan W. Ojala, Jens Billgren, John A. Latham, Leon F. Garcia-Martinez, Patricia Dianne Mcneill, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Подробнее
Номер записи: 73
10-10-2017 дата публикации

Methods of preventing inflammation and treating pain using anti-NGF compositions

Номер: US9783601B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

Monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.

Подробнее
Номер записи: 74
29-10-2019 дата публикации

Methods of preventing inflammation and treating pain using anti-NGF compositions

Номер: US10457727B2
Автор: Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.

Подробнее
Номер записи: 75
09-07-2019 дата публикации

Anti-NGF compositions and use thereof

Номер: US10344083B2
Автор: Benjamin H. Dutzar, Betty Yu-Ching Chang, Brian R. Kovacevich, Corinne C. Akatsuka, Danielle M. Mitchell, Erica A. Stewart, Ethan W. Ojala, Jens J. BILLGREN, John A. Latham, Leon F. Garcia-Martinez, Patricia Dianne Mcneill, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Подробнее
Номер записи: 76
12-03-2019 дата публикации

Anti-NGF antibodies and anti-NGF antibody fragments

Номер: US10227402B2
Автор: Benjamin H. Dutzar, Corinne C. Akatsuka, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Leon F. Garcia-Martinez, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.)

Подробнее
Номер записи: 77
23-06-2016 дата публикации

Humanized anti-acth antibodies and use thereof

Номер: CA2973819A1
Автор: Andrew L. Feldhaus, Benjamin H. Dutzar, Charlie KARASEK, Daniel S. Allison, Danielle MITCHELL, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, John Latham, Katie Anderson, Leon F. Garcia-Martinez, Michelle Scalley-Kim, Patricia Dianne Mcneill, Pei Fan
Принадлежит: Alder Biopharmaceuticals Inc

The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as CAH, FGD, Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders, depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

Подробнее
Номер записи: 78
13-02-2018 дата публикации

Antibodies to TNF α and use thereof

Номер: US9890214B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Ethan W. Ojala, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-α. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-α antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-α antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-α antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-α.

Подробнее
Номер записи: 79
18-09-2014 дата публикации

Antibody purification and purity monitoring

Номер: CA2905531A1
Автор: Daniel S. Allison, Ethan W. Ojala, Geoffrey F. Lee, Hoa Binh Do, John A. Latham, Leon F. Garcia-Martinez, Mark Young, Steven D. Davin
Принадлежит: Alder Biopharmaceuticals Inc

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.

Подробнее
Номер записи: 80
18-09-2014 дата публикации

Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Номер: CA2907570A1
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Daniel S. Allison, Ethan W. Ojala, Jens Billgren, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: Alder Biopharmaceuticals Inc

Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies.

Подробнее
Номер записи: 81
09-02-2021 дата публикации

Humanized anti-PACAP antibodies and uses thereof

Номер: US10913783B2
Автор: Benjamin H. Dutzar, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V H , V L , and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

Подробнее
Номер записи: 82
21-07-2016 дата публикации

Anti-glycoprotein antibodies and uses thereof

Номер: CA2974033A1
Автор: Amarjeet Singh, Benjamin DUTZAR, Daniel S. Allison, Ethan W. Ojala, Geoffrey F. Lee, Jenny A. Mulligan, Pamela Brown
Принадлежит: Alder Biopharmaceuticals Inc

A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated proteins, such as proteins produced by fungi. Assays using these anti-glycoprotein antibodies for monitoring the presence of glycoproteins in a sample are provided. Such methods can be used to monitor methods for production and/or purification of desired polypeptides, which may be used to modify process parameters to modify (e.g., decrease or increase) the amount of glycosylated polypeptide produced and/or present in the purified product. Also provided are methods of using the subject antibodies for detecting the level of expression and secretion of a polypeptide, and methods of using the subject antibodies to purify or deplete a glycoprotein from a sample. In exemplary embodiments, the desired polypeptide may be a multi-subunit protein, such as an antibody, which may be produced in a yeast, such as Pichia pastoris.

Подробнее
Номер записи: 83
17-08-2017 дата публикации

Anti-NGF compositions and use thereof

Номер: AU2017208339A1
Автор: Benjamin H. Dutzar, Betty Yu-Ching Chang, Brian R. Kovacevich, Corinne C. Akatsuka, Danielle M. Mitchell, Erica A. Stewart, Ethan W. Ojala, Jeffrey T.L. Smith, Jens Billgren, John A. Latham, Leon F. Garcia-Martinez, Patricia Dianne Mcneill, Pei Fan
Принадлежит: ALDERBIO HOLDINGS LLC

Abstract The present invention is directed to antibodies and fragments thereof having binding specificity for NGF, especially those that inhibit the interaction of NGF with TrkA and/or p75 or p75 and/or TrkA. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Подробнее
Номер записи: 84
18-09-2014 дата публикации

Antibody purification and purity monitoring

Номер: WO2014145744A1
Автор: Daniel S. Allison, Ethan W. Ojala, Geoffrey F. Lee, Hoa Binh Do, John A. Latham, Leon F. Garcia-Martinez, Mark Young, Steven D. Davin
Принадлежит: Alder Biopharmaceuticals, Inc.

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.

Подробнее
Номер записи: 85
22-11-2017 дата публикации

Anti-glycoprotein antibodies and uses thereof

Номер: EP3244738A1
Автор: Amarjeet Singh, Benjamin DUTZAR, Daniel S. Allison, Ethan W. Ojala, Geoffrey F. Lee, Jenny A. Mulligan, Pamela Brown
Принадлежит: Alder Biopharmaceuticals Inc

A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated proteins, such as proteins produced by fungi. Assays using these anti-glycoprotein antibodies for monitoring the presence of glycoproteins in a sample are provided. Such methods can be used to monitor methods for production and/or purification of desired polypeptides, which may be used to modify process parameters to modify ( e.g. , decrease or increase) the amount of glycosylated polypeptide produced and/or present in the purified product. Also provided are methods of using the subject antibodies for detecting the level of expression and secretion of a polypeptide, and methods of using the subject antibodies to purify or deplete a glycoprotein from a sample. In exemplary embodiments, the desired polypeptide may be a multi-subunit protein, such as an antibody, which may be produced in a yeast, such as Pichia pastoris.

Подробнее
Номер записи: 86
06-11-2014 дата публикации

Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Номер: WO2014146074A3
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Daniel S. Allison, Ethan W. Ojala, Jens Billgren, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: Alder Biopharmaceuticals, Inc.

Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies.

Подробнее
Номер записи: 87
21-10-2021 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US20210324068A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 88
20-06-2013 дата публикации

Anti-NGF compositions and use thereof

Номер: AU2011336470A1
Автор: Benjamin H. Dutzar, Betty Yu-Ching Chang, Brian R. Kovacevich, Corinne C. Akatsuka, Danielle M. Mitchell, Erica A. Stewart, Ethan W. Ojala, Jeffrey T.L. Smith, Jens Billgren, John A. Latham, Leon F. Garcia-Martinez, Patricia Dianne Mcneill, Pei Fan
Принадлежит: Alder Biopharmaceuticals Inc

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF, especially those that inhibit the interaction of NGF with TrkA and/or p75 or p75 and/or TrkA. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Подробнее
Номер записи: 89
24-11-2020 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US10844116B2
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 90
26-03-2024 дата публикации

Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies

Номер: US11938185B2
Автор: Benjamin H. Dutzar, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

Подробнее
Номер записи: 91
28-11-2023 дата публикации

Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies

Номер: US11827700B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: Vitaeris Inc

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Подробнее
Номер записи: 92
28-05-2024 дата публикации

Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion

Номер: US11993648B2
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 93
13-12-2016 дата публикации

Antibody purification and purity monitoring

Номер: US09518082B2
Автор: Daniel S. Allison, Ethan W. Ojala, Geoffrey F. Lee, Hoa Binh Do, John A. Latham, Leon F. Garcia-Martinez, Mark Young, Steven D. Davin
Принадлежит: ALDERBIO HOLDINGS LLC

Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris , and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.

Подробнее
Номер записи: 94